Clinical trial · Interventional
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS.
NCT07435038CI-TRIAL-00105285recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 19, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260919-000001
Summary
Brief summary (as posted)
Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
| Colorectal Cancer (CRC) | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Non-small Cell Lung Cancer (NSCLC) | Lung Non-Small Cell Carcinoma | ALIAS | 0.85 |
| Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Ductal Adenocarcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BPI-572270 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Study BPI-572270 in adults with specific RAS mutant advanced solid tumors
- description
- Capsules; Administer once a day on an empty stomach.
- interventionNames
- Drug: BPI-572270
Primary outcomes (3)
- measure
- DLT
- timeFrame
- up to 2 tears
- description
- Number of Participants with Dose-Limiting Toxicity (DLT)AEs, including incidence and severity of findings in laboratory values and vital signs
- measure
- RP2D
- timeFrame
- up to 2 tears
- description
- Determination of RP2D in the expansion phase
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed advanced solid tumor with RAS mutations identified through deoxyribonucleic acid (DNA) sequencing. * Have received prior standard therapy appropriate for tumor type and stage. * Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Adequate organ function. Exclusion Criteria: * Primary central nervous system (CNS) tumors active and untreated brain metastases. * Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication. * History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy
References
Publications (0)
Data not yet available
No reference posted for this study.